Scarica l'app Stockscreener
6.62
1.63%
-0.11
Dopo l'orario di chiusura:
6.62
Precedente Chiudi:
$6.73
Aprire:
$6.48
Volume 24 ore:
2.27M
Relative Volume:
1.15
Capitalizzazione di mercato:
$455.27M
Reddito:
$161.10M
Utile/perdita netta:
$-308.60M
Rapporto P/E:
-1.4176
EPS:
-4.67
Flusso di cassa netto:
$-259.90M
1 W Prestazione:
-4.06%
1M Prestazione:
-62.30%
6M Prestazione:
-73.53%
1 anno Prestazione:
-81.98%
Intervallo 1D:
$6.225
$6.63
Intervallo di 1 settimana:
$5.935
$6.86
Portata 52W:
$5.935
$39.34
Arvinas Inc Stock (ARVN) Company Profile
Nome
Arvinas Inc
Settore
Industria
Telefono
203-535-1456
Indirizzo
395 WINCHESTER AVE, NEW HAVEN, CT
Confronta ARVN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
6.62 | 455.27M | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
475.49 | 122.24B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
546.39 | 59.73B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
546.22 | 33.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
226.28 | 29.29B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
208.31 | 22.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-13 | Downgrade | Goldman | Buy → Neutral |
| 2025-03-12 | Downgrade | Wedbush | Outperform → Neutral |
| 2025-03-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-10 | Iniziato | BTIG Research | Buy |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-02-28 | Reiterato | Oppenheimer | Outperform |
| 2024-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2024-02-01 | Iniziato | Goldman | Buy |
| 2023-12-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-11-20 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-10-23 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-01-12 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-01-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | Iniziato | Barclays | Overweight |
| 2022-06-21 | Iniziato | Jefferies | Hold |
| 2022-05-09 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-04-06 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-02-11 | Ripresa | BMO Capital Markets | Outperform |
| 2022-02-10 | Iniziato | Wells Fargo | Overweight |
| 2022-01-19 | Iniziato | Goldman | Buy |
| 2021-12-07 | Iniziato | Cowen | Outperform |
| 2021-10-14 | Iniziato | SVB Leerink | Outperform |
| 2021-09-30 | Iniziato | Stifel | Buy |
| 2021-09-09 | Iniziato | BofA Securities | Buy |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-21 | Iniziato | Truist | Buy |
| 2021-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-12-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-06-01 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-05-12 | Iniziato | Oppenheimer | Perform |
| 2019-12-19 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-25 | Iniziato | Guggenheim | Buy |
| 2019-10-24 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-09-25 | Iniziato | Wedbush | Outperform |
| 2019-09-12 | Iniziato | BMO Capital Markets | Outperform |
| 2019-08-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-06-05 | Downgrade | Citigroup | Buy → Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-10-22 | Iniziato | Citigroup | Buy |
| 2018-10-22 | Iniziato | Goldman | Neutral |
| 2018-10-22 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Arvinas Inc Borsa (ARVN) Ultime notizie
American Century Companies Inc. Lowers Stock Position in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas (ARVN) Reports Positive Phase 3 Trial Results in Breast Cancer Treatment - GuruFocus
Arvinas stock target cut to $21 from $65 at Truist Securities - Investing.com
Arvinas, Inc. (ARVN): Among Stocks Under $10 that Will Triple - Insider Monkey
After Plunging -25.42% in 4 Weeks, Here's Why the Trend Might Reverse for Arvinas (ARVN) - Yahoo Finance
HC Wainwright Reaffirms Buy Rating for Arvinas (NASDAQ:ARVN) - MarketBeat
Truist Slashes Price Target on Arvinas to $21 From $65, Keeps Buy Rating - MarketScreener
JPMorgan Chase & Co. Sells 472,225 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Vanguard Group Inc. Grows Position in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
10 Stocks Under $10 that Will Triple - Insider Monkey
H.C. Wainwright maintains $81 target on Arvinas stock post-data By Investing.com - Investing.com India
H.C. Wainwright maintains $81 target on Arvinas stock post-data - Investing.com
Finepoint Capital LP Buys 139,400 Shares of Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Norges Bank Acquires New Shares in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Edmond DE Rothschild Holding S.A. Takes $1.53 Million Position in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas stock plunges to 52-week low at $6.46 amid market rout - Investing.com Canada
Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study - Benzinga
Arvinas stock plunges to 52-week low at $6.46 amid market rout By Investing.com - Investing.com South Africa
Arvinas Holding Company Unveils Promising ARV-102 Trial Results - TipRanks
Arvinas : MoneyGram and Mastercard collaborate to advance digital money movement - MarketScreener
Arvinas’ PROTAC halves protein suspected to play role in Parkinson’s - Yahoo
Arvinas Presents First-in-Human Data For ARV-102 In Neurodegenerative Diseases, Stock Down - Nasdaq
Arvinas Says First-in-Human Data for ARV-102 Shows Substantial Reduction of LRRK2 - MarketScreener
Arvinas Presents First-in-Human Data for Investigational - GlobeNewswire
Game-Changing Parkinson's Drug Shows 90% Target Reduction in First Human Trial - Stock Titan
We Think Arvinas (NASDAQ:ARVN) Can Afford To Drive Business Growth - Yahoo Finance
Arvinas, Inc. (NASDAQ:ARVN) Short Interest Update - MarketBeat
BIT Capital GmbH Has $5.05 Million Holdings in Arvinas, Inc. (NASDAQ:ARVN) - MarketBeat
Arvinas (NASDAQ:ARVN) Hits New 52-Week LowHere's What Happened - MarketBeat
Where are the Opportunities in (ARVN) - news.stocktradersdaily.com
Humacyte price target lowered to $8 from $10 at BTIG - Yahoo Finance
Arvinas stock hits 52-week low at $7.91 amid market challenges - Investing.com India
Arvinas stock hits 52-week low at $7.91 amid market challenges By Investing.com - Investing.com South Africa
Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer’s & Parkinson’s Diseases - GlobeNewswire
Groundbreaking First Human Data: New PROTAC Drug Takes Aim at Parkinson's Disease - Stock Titan
Arvinas (NASDAQ:ARVN) Shares Down 5.1%Time to Sell? - MarketBeat
Arvinas FY2025 EPS Forecast Increased by Cantor Fitzgerald - MarketBeat
Noah Berkowitz Sells 8,658 Shares of Arvinas, Inc. (NASDAQ:ARVN) Stock - MarketBeat
Arvinas (NASDAQ:ARVN) Trading Up 4%Here's Why - MarketBeat
Wedbush Brokers Raise Earnings Estimates for Arvinas - MarketBeat
Arvinas Inc Azioni (ARVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.35%
10.53%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):